AGYTF / Allergy Therapeutics primed for a pivotal year

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has said it will be presenting key scientific findings from its research portfolio at the European Acade more_horizontal

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has announced a significant milestone in its innovative peanut allergy treatment with the successful co more_horizontal

Allergy Therapeutics has arranged a financing package from two of the major shareholders that will enable it to carry on with planned trials of its ha more_horizontal

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF), the commercial-stage biotech company, has started administering its groundbreaking short-course peanut more_horizontal

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) said it expects revenue for the first six months to be £39.9mln, down 18% compared to the same period l more_horizontal

Allergy Therapeutics shed more than half of its value as it warned that audited results for the year to June 2022 would not be ready by the end of thi more_horizontal

Allergy Therapeutics said it had dosed its first patient in a phase III trial for a new grass pollen vaccine, while screening is underway for a safety more_horizontal

Allergy Therapeutics said it expects net profits this year to meet net profit forecasts for the year just ended even on reduced revenues. The hay fev more_horizontal